What is the 13F Pro Quality Score for TECH?

13F Pro ranks BIO-TECHNE Corp (TECH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TECH's current score at https://13fpro.ai/research/TECH (free sign-up required for the full ranking).

Which hedge funds own the most TECH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TECH include BlackRock,, VANGUARD CAPITAL MANAGEMENT, MORGAN STANLEY. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TECH as soon as new 13F filings post.

Where does 13F Pro source TECH data?

All BIO-TECHNE Corp fundamentals and ownership data come directly from SEC EDGAR. BIO-TECHNE Corp files with the SEC under CIK 842023. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TECH in?

BIO-TECHNE Corp (TECH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TECH research updated on 13F Pro?

TECH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIO-TECHNE Corp(TECH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 842023 TECH stock profile & AI dashboard →

13F Pro Quality Score

59.6/100

Rank #911 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

45.6/100

Profitability

72.4/100

Balance Sheet

74.3/100

Earnings Quality

32.7/100

Free Cash Flow

75.3/100

Institutional Flow

48.6/100

Revenue Scale

53.0/100

Dilution Risk

31.7/100

TECH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BIO-TECHNE Corp (TECH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TECH at 59.6/100 on a 32-signal composite quality model, placing it at rank #911 of 2,879 stocks — the top half of the AI-ranked universe. TECH scores in the top quartile across free cash flow (75.3). Areas of concern include earnings quality (32.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), BIO-TECHNE Corp reports quarterly revenue of $311.4M, net income of $51.0M, free cash flow of $77.6M. Top institutional holders of TECH by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, MORGAN STANLEY, based on the most recent SEC filings. TECH trades on the Nasdaq exchange and files with the SEC under CIK 842023. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TECH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIO-TECHNE Corp directly from SEC EDGAR. BIO-TECHNE Corp's 13F Pro composite quality score has ranged between 8 and 74 since 2021, currently 59.6 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about BIO-TECHNE Corp

Quirks, history, and lore behind TECH — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. life sciences company · mid-cap · listed on Nasdaq · headquartered in Minnesota.
2
The Numbers
Annual revenue in the range of roughly $1 billion, with operating margins that would make most pharma CFOs jealous — high-value reagents and instruments are a lucrative business.
3
The History
Founded in the 1970s, it grew by acquiring specialized life-science tool makers and has spent decades quietly building a portfolio that underpins research labs worldwide.
4
The Secret
It doesn't make drugs — it makes the proteins, antibodies, and assay kits that other scientists use to discover drugs, meaning it profits from every lab bench in the pipeline.
5
The Lore
Its R&D Systems brand is a staple citation in thousands of peer-reviewed papers, and its Tocris subsidiary supplies pharmacological tools to neuroscience researchers globally.
6
The Giveaway
The parent company's name literally fuses biology and technology, and its Nasdaq ticker is simply TECH — the rare case where the symbol is more famous than the full name.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$311.4M

Net Income

Q3 2026

$51.0M

Free Cash Flow

Q3 2026

$77.6M

ROIC

Q3 2026

3.3%

D/E Ratio

Q3 2026

0.10

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+5.2% YoY

$1.22BFY 2025

FY22 $1.11BFY23 $1.14BFY24 $1.16BFY25 $1.22B

Net Income

-56.3% YoY

$73.4MFY 2025

FY22 $272.1MFY23 $285.3MFY24 $168.1MFY25 $73.4M

Operating Income

-50.5% YoY

$102.3MFY 2025

FY22 $296.6MFY23 $298.9MFY24 $206.7MFY25 $102.3M

EPS (Diluted)

-56.2% YoY

$0.46FY 2025

FY22 $0.41FY23 $1.76FY24 $1.05FY25 $0.46

Total Assets

-5.4% YoY

$2.56BFY 2025

FY22 $2.29BFY23 $2.64BFY24 $2.70BFY25 $2.56B

Total Debt

+8.5% YoY

$346.0MFY 2025

FY22 $255.9MFY23 $350.0MFY24 $319.0MFY25 $346.0M

Op. Cash Flow

-3.8% YoY

$287.6MFY 2025

FY22 $325.3MFY23 $254.4MFY24 $299.0MFY25 $287.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.22B +5.2%	$1.16B +2.0%	$1.14B +2.8%	$1.11B +18.7%	$931.0M +26.0%	$738.7M
Net Income	$73.4M -56.3%	$168.1M -41.1%	$285.3M +4.9%	$272.1M +93.8%	$140.4M -38.8%	$229.3M
Operating Income	$102.3M -50.5%	$206.7M -30.9%	$298.9M +0.8%	$296.6M +25.0%	$237.3M +50.7%	$157.4M
EPS (Diluted)	$0.46 -56.2%	$1.05 -40.3%	$1.76 +324.1%	$0.41 +90.8%	$0.22 -85.1%	$1.46
Total Assets	$2.56B -5.4%	$2.70B +2.5%	$2.64B +15.0%	$2.29B +1.4%	$2.26B +11.6%	$2.03B
Total Debt	$346.0M +8.5%	$319.0M -8.9%	$350.0M +36.8%	$255.9M -25.0%	$341.3M -4.3%	$356.7M
Operating Cash Flow	$287.6M -3.8%	$299.0M +17.5%	$254.4M -21.8%	$325.3M -7.6%	$352.2M +71.6%	$205.2M

AI Insight: TECH Financial Trends

TECH rebounded sharply in Q1 2026 with net income +33% QoQ and operating income at the highest level in the dataset, while debt fell to a two-year low.

• Operating income surged to $75M in Q1 2026, up 39% from $54M in Q4 2025, reaching best level since data began.

• Net income recovered to $51M in Q1 2026 after Q2 2025 loss of $18M; operating cash flow remains strong at $87M.

• Total debt declined to $200M in Q1 2026 from $346M in Q2 2025, the lowest level in the eight-quarter period.

⚠ Revenue flat to slightly declining over eight quarters ($306M→$311M), despite recent rebound; Q3 2025 dipped to $287M.

⚠ Q2 2025 saw $18M net loss and $24M operating loss; causes and sustainability of recovery require clarification.

AI Insight: TECH Ratio Trends

Operating margin surged to 24.2% in Q1 2026, with ROIC jumping to 13.2%—a sharp rebound from weakness a year prior.

• Operating margin expanded from 12.7% (TTM) to 24.2% in Q1 2026; NPM rose to 16.4% from 9.0%.

• ROIC climbed to 13.2% in Q1 2026 from 6.7% in TTM; ROA reached 8.0% versus 4.3% trailing.

• Debt-to-equity improved to 0.10 in Q1 2026, lowest since Q2 2024, strengthening balance sheet.

⚠ Q1 2026 metrics may reflect seasonal strength or one-offs; TTM lags latest quarter significantly.

⚠ Extreme Q2 2025 loss (-7.5% OpMargin, -27.6% ROIC) signals prior operational disruption; durability unclear.

Get alerted when TECH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIO-TECHNE Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TECH

BlackRock, Inc.
$640.9M12,264,513 sh
VANGUARD CAPITAL MANAGEMENT LLC
$532.0M10,179,709 sh
MORGAN STANLEY
$445.9M8,532,873 sh
FMR LLC
$412.9M7,899,928 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$338.7M6,480,337 sh
STATE STREET CORP
$306.7M5,868,396 sh
WELLINGTON MANAGEMENT GROUP LLP
$267.6M5,120,185 sh
GEODE CAPITAL MANAGEMENT, LLC
$266.8M5,112,420 sh
MAVERICK CAPITAL LTD
$247.7M4,739,721 sh
Invesco Ltd.
$239.8M4,588,706 sh

Fund	Value	Shares
BlackRock, Inc.	$640.9M	12,264,513
VANGUARD CAPITAL MANAGEMENT LLC	$532.0M	10,179,709
MORGAN STANLEY	$445.9M	8,532,873
FMR LLC	$412.9M	7,899,928
VANGUARD PORTFOLIO MANAGEMENT LLC	$338.7M	6,480,337
STATE STREET CORP	$306.7M	5,868,396
WELLINGTON MANAGEMENT GROUP LLP	$267.6M	5,120,185
GEODE CAPITAL MANAGEMENT, LLC	$266.8M	5,112,420
MAVERICK CAPITAL LTD	$247.7M	4,739,721
Invesco Ltd.	$239.8M	4,588,706

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TECH on your watchlist

Track score changes the day BIO-TECHNE Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TECH a good stock to buy?

13F Pro's AI-powered analysis of BIO-TECHNE Corp (TECH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TECH are available on the TECH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TECH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TECH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIO-TECHNE Corp's investment landscape.